HRP20140371T1 - Arilpiridini kao inhibitori sinteze aldosterona - Google Patents
Arilpiridini kao inhibitori sinteze aldosterona Download PDFInfo
- Publication number
- HRP20140371T1 HRP20140371T1 HRP20140371AT HRP20140371T HRP20140371T1 HR P20140371 T1 HRP20140371 T1 HR P20140371T1 HR P20140371A T HRP20140371A T HR P20140371AT HR P20140371 T HRP20140371 T HR P20140371T HR P20140371 T1 HRP20140371 T1 HR P20140371T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- pyridin
- cyclopropyl
- ethanesulfonamide
- halo
- Prior art date
Links
- -1 Aryl pyridine Chemical compound 0.000 title claims 10
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000010496 Heart Arrest Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 229960002478 aldosterone Drugs 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000003205 diastolic effect Effects 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- RSOJSFYJLQADDM-UHFFFAOYSA-N ethanesulfonamide Chemical compound [CH2]CS(N)(=O)=O RSOJSFYJLQADDM-UHFFFAOYSA-N 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- VVFGWGFXFJUZHN-LJQANCHMSA-N n-[(r)-[5-(4-cyano-2-methoxyphenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C(=CC(=CC=2)C#N)OC)CC1 VVFGWGFXFJUZHN-LJQANCHMSA-N 0.000 claims 2
- SRSZAQXMZUVWQU-GOSISDBHSA-N n-[(r)-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C=C(F)C(C#N)=CC=2)CC1 SRSZAQXMZUVWQU-GOSISDBHSA-N 0.000 claims 2
- KCHHHGRFMSWSFF-SFHVURJKSA-N n-[(s)-[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C=C(Cl)C(C#N)=CC=2)CC1 KCHHHGRFMSWSFF-SFHVURJKSA-N 0.000 claims 2
- KZTMXEYWZCAYNV-UHFFFAOYSA-N n-[[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]methanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C(C#N)=CC=2)=CC=1C(NS(=O)(=O)C)C1CC1 KZTMXEYWZCAYNV-UHFFFAOYSA-N 0.000 claims 2
- FGKOVGZUXTYAFP-UHFFFAOYSA-N n-[[5-(4-cyano-3-methoxyphenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(OC)C(C#N)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 FGKOVGZUXTYAFP-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 208000009888 Adrenocortical Adenoma Diseases 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 101100439662 Arabidopsis thaliana CHR5 gene Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 208000019025 Hypokalemia Diseases 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010027603 Migraine headaches Diseases 0.000 claims 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims 1
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 108091008698 baroreceptors Proteins 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 231100001012 cardiac lesion Toxicity 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- UUNZMQGLNBMSKR-UHFFFAOYSA-N methyl 2-[[[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]-ethylsulfonylamino]acetate Chemical compound C=1N=CC(C=2C=C(Cl)C(C#N)=CC=2)=CC=1C(N(CC(=O)OC)S(=O)(=O)CC)C1CC1 UUNZMQGLNBMSKR-UHFFFAOYSA-N 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- KCHHHGRFMSWSFF-GOSISDBHSA-N n-[(r)-[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C=C(Cl)C(C#N)=CC=2)CC1 KCHHHGRFMSWSFF-GOSISDBHSA-N 0.000 claims 1
- WYNMBLOJFUFQSI-LJQANCHMSA-N n-[(r)-[5-(4-cyano-3-methylphenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C=C(C)C(C#N)=CC=2)CC1 WYNMBLOJFUFQSI-LJQANCHMSA-N 0.000 claims 1
- VVFGWGFXFJUZHN-IBGZPJMESA-N n-[(s)-[5-(4-cyano-2-methoxyphenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C(=CC(=CC=2)C#N)OC)CC1 VVFGWGFXFJUZHN-IBGZPJMESA-N 0.000 claims 1
- SRSZAQXMZUVWQU-SFHVURJKSA-N n-[(s)-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C=C(F)C(C#N)=CC=2)CC1 SRSZAQXMZUVWQU-SFHVURJKSA-N 0.000 claims 1
- WYNMBLOJFUFQSI-IBGZPJMESA-N n-[(s)-[5-(4-cyano-3-methylphenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C=C(C)C(C#N)=CC=2)CC1 WYNMBLOJFUFQSI-IBGZPJMESA-N 0.000 claims 1
- GNNCQHXNMNEOEV-UHFFFAOYSA-N n-[1-[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-2-methylpropyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC(C(C)C)C1=CN=CC(C=2C=C(Cl)C(C#N)=CC=2)=C1 GNNCQHXNMNEOEV-UHFFFAOYSA-N 0.000 claims 1
- UIKZJIISZHKQQD-UHFFFAOYSA-N n-[1-[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]butyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC(CCC)C1=CN=CC(C=2C=C(Cl)C(C#N)=CC=2)=C1 UIKZJIISZHKQQD-UHFFFAOYSA-N 0.000 claims 1
- GHVAMRPOCFGUOI-UHFFFAOYSA-N n-[1-[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]ethyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC(C)C1=CN=CC(C=2C=C(Cl)C(C#N)=CC=2)=C1 GHVAMRPOCFGUOI-UHFFFAOYSA-N 0.000 claims 1
- MITVGNGZNBCXRB-UHFFFAOYSA-N n-[1-[5-(4-cyano-3-methoxyphenyl)pyridin-3-yl]ethyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC(C)C1=CN=CC(C=2C=C(OC)C(C#N)=CC=2)=C1 MITVGNGZNBCXRB-UHFFFAOYSA-N 0.000 claims 1
- XDCWFWQTIHEEKP-UHFFFAOYSA-N n-[1-[5-(4-cyano-3-methylphenyl)pyridin-3-yl]-2,2,2-trifluoroethyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC(C(F)(F)F)C1=CN=CC(C=2C=C(C)C(C#N)=CC=2)=C1 XDCWFWQTIHEEKP-UHFFFAOYSA-N 0.000 claims 1
- AARNKXHCQPGOAH-UHFFFAOYSA-N n-[[4-chloro-5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]-n-methylmethanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C(C#N)=CC=2)=C(Cl)C=1C(N(C)S(C)(=O)=O)C1CC1 AARNKXHCQPGOAH-UHFFFAOYSA-N 0.000 claims 1
- QNEMFUDCKLQDMG-UHFFFAOYSA-N n-[[5-(1,3-benzodioxol-5-yl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3OCOC3=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 QNEMFUDCKLQDMG-UHFFFAOYSA-N 0.000 claims 1
- WUOHAELXTQEOOT-UHFFFAOYSA-N n-[[5-(1,3-benzothiazol-5-yl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3N=CSC3=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 WUOHAELXTQEOOT-UHFFFAOYSA-N 0.000 claims 1
- SOJXIUTXQCSPHE-UHFFFAOYSA-N n-[[5-(1-benzofuran-5-yl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3C=COC3=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 SOJXIUTXQCSPHE-UHFFFAOYSA-N 0.000 claims 1
- DUGRYOPJEPNIAG-UHFFFAOYSA-N n-[[5-(1-benzothiophen-2-yl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2SC3=CC=CC=C3C=2)=CC=1C(NS(=O)(=O)CC)C1CC1 DUGRYOPJEPNIAG-UHFFFAOYSA-N 0.000 claims 1
- MNIDIHWMANQKCX-UHFFFAOYSA-N n-[[5-(2-chlorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C(=CC=CC=2)Cl)=CC=1C(NS(=O)(=O)CC)C1CC1 MNIDIHWMANQKCX-UHFFFAOYSA-N 0.000 claims 1
- OKJIGSCWEPHSSB-UHFFFAOYSA-N n-[[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopentylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C(C#N)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CCCC1 OKJIGSCWEPHSSB-UHFFFAOYSA-N 0.000 claims 1
- ZRKGVHLFONKKKY-UHFFFAOYSA-N n-[[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]-n-(2-hydroxyethyl)ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C(C#N)=CC=2)=CC=1C(N(CCO)S(=O)(=O)CC)C1CC1 ZRKGVHLFONKKKY-UHFFFAOYSA-N 0.000 claims 1
- CCUXXDAJXRXCFE-UHFFFAOYSA-N n-[[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]-n-(2-methylpropyl)ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C(C#N)=CC=2)=CC=1C(N(CC(C)C)S(=O)(=O)CC)C1CC1 CCUXXDAJXRXCFE-UHFFFAOYSA-N 0.000 claims 1
- VBRRBXVENRHJPA-UHFFFAOYSA-N n-[[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]-n-methylethanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C(C#N)=CC=2)=CC=1C(N(C)S(=O)(=O)CC)C1CC1 VBRRBXVENRHJPA-UHFFFAOYSA-N 0.000 claims 1
- GTYCYCZDLXCWCA-UHFFFAOYSA-N n-[[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-cyclopropylmethyl]propane-2-sulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C(C#N)=CC=2)=CC=1C(NS(=O)(=O)C(C)C)C1CC1 GTYCYCZDLXCWCA-UHFFFAOYSA-N 0.000 claims 1
- YQCKZCJOSRVLTC-UHFFFAOYSA-N n-[[5-(3-chloro-4-fluorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C(F)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 YQCKZCJOSRVLTC-UHFFFAOYSA-N 0.000 claims 1
- VPALXZHNQQPQSN-UHFFFAOYSA-N n-[[5-(3-chlorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 VPALXZHNQQPQSN-UHFFFAOYSA-N 0.000 claims 1
- FTZQHCFZLNBBBC-UHFFFAOYSA-N n-[[5-(4-chlorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=CC(Cl)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 FTZQHCFZLNBBBC-UHFFFAOYSA-N 0.000 claims 1
- OCQZCGOOKDVZLC-UHFFFAOYSA-N n-[[5-(4-cyano-2-fluorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C(=CC(=CC=2)C#N)F)=CC=1C(NS(=O)(=O)CC)C1CC1 OCQZCGOOKDVZLC-UHFFFAOYSA-N 0.000 claims 1
- SGEUCCVWWULUKG-MXHDAQFASA-N n-[[5-(4-cyano-2-fluorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide;n-[(s)-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C1([C@H](NS(=O)(=O)CC)C=2C=C(C=NC=2)C=2C=C(F)C(C#N)=CC=2)CC1.C=1N=CC(C=2C(=CC(=CC=2)C#N)F)=CC=1C(NS(=O)(=O)CC)C1CC1 SGEUCCVWWULUKG-MXHDAQFASA-N 0.000 claims 1
- WBLYCYRTLGKTTR-UHFFFAOYSA-N n-[[5-(5-cyano-1-benzofuran-2-yl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2OC3=CC=C(C=C3C=2)C#N)=CC=1C(NS(=O)(=O)CC)C1CC1 WBLYCYRTLGKTTR-UHFFFAOYSA-N 0.000 claims 1
- UEELRBWWAHOEMG-UHFFFAOYSA-N n-[[5-(6-chloro-1-methylbenzimidazol-2-yl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NCC1=CN=CC(C=2N(C3=CC(Cl)=CC=C3N=2)C)=C1 UEELRBWWAHOEMG-UHFFFAOYSA-N 0.000 claims 1
- DCWZIYCLQHGBRE-UHFFFAOYSA-N n-[[5-(6-cyanonaphthalen-2-yl)pyridin-3-yl]-cyclopropylmethyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3C=CC(=CC3=CC=2)C#N)=CC=1C(NS(=O)(=O)CC)C1CC1 DCWZIYCLQHGBRE-UHFFFAOYSA-N 0.000 claims 1
- LEDUQFBMAMLCIM-UHFFFAOYSA-N n-[cyclopropyl-(5-naphthalen-1-ylpyridin-3-yl)methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C3=CC=CC=C3C=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 LEDUQFBMAMLCIM-UHFFFAOYSA-N 0.000 claims 1
- RRKHUJAFSFAIKB-UHFFFAOYSA-N n-[cyclopropyl-(5-quinolin-6-ylpyridin-3-yl)methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3C=CC=NC3=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 RRKHUJAFSFAIKB-UHFFFAOYSA-N 0.000 claims 1
- XCCUYXAHRUGOOH-UHFFFAOYSA-N n-[cyclopropyl-[5-(1-methylindol-5-yl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3C=CN(C)C3=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 XCCUYXAHRUGOOH-UHFFFAOYSA-N 0.000 claims 1
- WAVHJLJLOKAMKK-UHFFFAOYSA-N n-[cyclopropyl-[5-(1h-indol-5-yl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3C=CNC3=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 WAVHJLJLOKAMKK-UHFFFAOYSA-N 0.000 claims 1
- QCYDSXVNCFRGJR-UHFFFAOYSA-N n-[cyclopropyl-[5-(2,3-dichlorophenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C(=C(Cl)C=CC=2)Cl)=CC=1C(NS(=O)(=O)CC)C1CC1 QCYDSXVNCFRGJR-UHFFFAOYSA-N 0.000 claims 1
- OGFQIVMUYNWXGQ-UHFFFAOYSA-N n-[cyclopropyl-[5-(2,3-dihydro-1-benzofuran-5-yl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3CCOC3=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 OGFQIVMUYNWXGQ-UHFFFAOYSA-N 0.000 claims 1
- ISLIISIHSZSHGJ-UHFFFAOYSA-N n-[cyclopropyl-[5-(2,4,6-trimethylphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C(=CC(C)=CC=2C)C)=CC=1C(NS(=O)(=O)CC)C1CC1 ISLIISIHSZSHGJ-UHFFFAOYSA-N 0.000 claims 1
- OGFWMBNJJJWGPH-UHFFFAOYSA-N n-[cyclopropyl-[5-(2,4-dichlorophenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C(=CC(Cl)=CC=2)Cl)=CC=1C(NS(=O)(=O)CC)C1CC1 OGFWMBNJJJWGPH-UHFFFAOYSA-N 0.000 claims 1
- QPUSGPIHDDFFQO-UHFFFAOYSA-N n-[cyclopropyl-[5-(2,4-dimethoxyphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C(=CC(OC)=CC=2)OC)=CC=1C(NS(=O)(=O)CC)C1CC1 QPUSGPIHDDFFQO-UHFFFAOYSA-N 0.000 claims 1
- RSRMEGSEFVWEIQ-UHFFFAOYSA-N n-[cyclopropyl-[5-(2-methoxyphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C(=CC=CC=2)OC)=CC=1C(NS(=O)(=O)CC)C1CC1 RSRMEGSEFVWEIQ-UHFFFAOYSA-N 0.000 claims 1
- LZESQGXTVMEZCU-UHFFFAOYSA-N n-[cyclopropyl-[5-(3,5-dichlorophenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(Cl)C=C(Cl)C=2)=CC=1C(NS(=O)(=O)CC)C1CC1 LZESQGXTVMEZCU-UHFFFAOYSA-N 0.000 claims 1
- ZNTWNOKTZKRRIG-UHFFFAOYSA-N n-[cyclopropyl-[5-(3,5-dimethylphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(C)C=C(C)C=2)=CC=1C(NS(=O)(=O)CC)C1CC1 ZNTWNOKTZKRRIG-UHFFFAOYSA-N 0.000 claims 1
- JEHKKIXOQDFMEU-UHFFFAOYSA-N n-[cyclopropyl-[5-(3-fluoro-4-methoxyphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(F)C(OC)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 JEHKKIXOQDFMEU-UHFFFAOYSA-N 0.000 claims 1
- YBYJIIJAMGOOGC-UHFFFAOYSA-N n-[cyclopropyl-[5-(3-fluorophenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(F)C=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 YBYJIIJAMGOOGC-UHFFFAOYSA-N 0.000 claims 1
- PPIYMGWAALPAER-UHFFFAOYSA-N n-[cyclopropyl-[5-(4-ethoxyphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C1=CC(OCC)=CC=C1C1=CN=CC(C(NS(=O)(=O)CC)C2CC2)=C1 PPIYMGWAALPAER-UHFFFAOYSA-N 0.000 claims 1
- XMVKUPHDFZFYEE-UHFFFAOYSA-N n-[cyclopropyl-[5-(4-ethylsulfanylphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C1=CC(SCC)=CC=C1C1=CN=CC(C(NS(=O)(=O)CC)C2CC2)=C1 XMVKUPHDFZFYEE-UHFFFAOYSA-N 0.000 claims 1
- NVQUXPHFKFXUTC-UHFFFAOYSA-N n-[cyclopropyl-[5-(4-fluoro-3-methylphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C(C)C(F)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 NVQUXPHFKFXUTC-UHFFFAOYSA-N 0.000 claims 1
- RVKULBUKYKRYCN-UHFFFAOYSA-N n-[cyclopropyl-[5-(4-fluorophenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=CC(F)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 RVKULBUKYKRYCN-UHFFFAOYSA-N 0.000 claims 1
- UTXAAPXZZYMFDV-UHFFFAOYSA-N n-[cyclopropyl-[5-(4-methoxyphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=CC(OC)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 UTXAAPXZZYMFDV-UHFFFAOYSA-N 0.000 claims 1
- XMFQHLAQLZHQNI-UHFFFAOYSA-N n-[cyclopropyl-[5-(4-methylsulfanylphenyl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=CC(SC)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 XMFQHLAQLZHQNI-UHFFFAOYSA-N 0.000 claims 1
- AOZKUHHNIYMWDS-UHFFFAOYSA-N n-[cyclopropyl-[5-(6-methoxynaphthalen-2-yl)pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=C3C=CC(OC)=CC3=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 AOZKUHHNIYMWDS-UHFFFAOYSA-N 0.000 claims 1
- LACYFAYGSMSJFL-UHFFFAOYSA-N n-[cyclopropyl-[5-[4-(trifluoromethoxy)phenyl]pyridin-3-yl]methyl]ethanesulfonamide Chemical compound C=1N=CC(C=2C=CC(OC(F)(F)F)=CC=2)=CC=1C(NS(=O)(=O)CC)C1CC1 LACYFAYGSMSJFL-UHFFFAOYSA-N 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000013435 necrotic lesion Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000024896 potassium deficiency disease Diseases 0.000 claims 1
- 210000001774 pressoreceptor Anatomy 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000003966 vascular damage Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (14)
1. Spoj, naznačen time, da ima formulu (I’):
[image]
ili njegova farmaceutski prihvatljiva sol, gdje A je -CHR5-;
Prsten C je fenil ili 5- ili 6-člani heteroaril;
R1 je C1-7alkil, haloalkil, C3-7cikloalkil, C6-10aril,
C6-10aril-C1-7alkil, C6-10ariloksi-C1-7alkil, heteroaril ili heterociklil, u kojoj su alkil, aril, heteroaril, heterociklil opcijski supstituirani s 1 do 5 R7;
R2 je H, C1-7alkil, halo-C1-7alkil, C3-7cikloalkil, C3-7cikloalkil-C1-7alkil, hidroksi-C1-7alkil, C1-7alkil-OC(O)C1-7alkil, C1-7alkoksi-C1-7alkil, heteroaril, heterociklil ili C6-10aril; pri čemu su aril i heteroaril opcijski supstituirani sa sljedećima: hidroksi, C1-7alkoksi, C1-7alkil, halo-C1-7alkil, halo, CN ili C3-7cikloalkil;
R3 je H, halo, C1-7alkil, halo-C1-7alkil, C3-7cikloalkil, cijano, C1-7alkoksi, hidroksi, nitro, -NH2, -NH(C1-7alkil) ili -N(C1-7alkil)2;
svaki R4 je neovisno odabran iz skupine koja se sastoji od sljedećih: halo, C1-7alkil, halo-C1-7alkil, C3-7cikloalkil, cijano, -NH2, -NH(C1-7alkil), -N(C1-7alkil)2, C1-7alkoksi, halo-C1-7alkoksi, hidroksi, karboksi, nitro, sulfonil, sulfamoil, sulfonamido, C6-10aril, heterociklil, C6-10ariloksi, heterocikliloksi, -SH, -S-C1-7alkil, -C(O)O-C6-10aril, -C(O)O-heterociklil, -C(O)O-heteroaril, -C(O)NR2-C1-7alkil, -C(O)NR2-C6-10aril, -C(O)NR2-heteroaril, -C(O)NR2-heterociklil, - NR2C(O)-C1-7alkil, -NR2C(O)-C6-10aril, -NR2C(O)-heteroaril, -NR2C(O)-heterociklil, -OC(O)-C1-7alkil, -OC(O)-C6-10aril, -OC(O)-heteroaril i -OC(O)-heterociklil;
pri čemu
R4 je opcijski supstituiran s 1 do 5 R7; ili
dvije susjedne skupine R4 s atomima na koje su priključeni, mogu tvoriti fenil ili 5-ili 6-člani prsten heteroarila, u kojem spomenuti fenil ili prsten heteroarila je opcijski supstituiran s 1 do 4 R8;
R6 je C1-7alkil, C3-7cikloalkil, halo-C1-7alkil, heterociklil, heteroaril ili C6-10aril;
svaki R7 je neovisno odabran iz skupine koja se sastoji od sljedećih: halo, C1-7alkil, C3-7cikloalkil, C1-7alkoksi, C6-10ariloksi, heterociklil, C6-10aril, heteroaril, CN i halo-C1-7alkil;
svaki R8 je neovisno odabran iz skupine koja se sastoji od sljedećih: halo, C1-7alkil, halo-C1-7alkil, C1-7alkoksi, CN i halo-C1-7alkoksi; ili
R2 i R3; R1 i R2; R1 i R5; R1 i R3; ili R2 i R5, s atomima na koje su priključeni, mogu tvoriti 4- do 7-člani heterociklil; ili R3 i R5, zajedno s atomima na koje su priključeni, mogu tvoriti C5-7cikloalkil; i
pritom svaki heteroaril je monociklički aromatski prsten koji sadrži 5 ili 6 atoma prstena odabranih od atoma ugljika i 1 do 5 heteroatoma, i svaki heterociklil je monociklički zasićen ili djelomično zasićen ali ne-aromatski dio sadrži 4 do 7 atoma prstena odabranih od atoma ugljika i 1 do 3 heteroatoma; i
svaki heteroatom je O, N ili S; i
p je 0, 1, 2, 3, 4 ili 5, uz uvjet da Prsten C zajedno sa dvije susjedne skupine R4 ne tvori 2-indol.
2. Spoj prema zahtjevu 1, naznačen time, da ima formulu (II):
[image]
ili njegova farmaceutski prihvatljiva sol, gdje A je -CHR5-;
R1 je C1-7alkil, halo-C1-7alkil, C3-7cikloalkil, C6-10aril, C6-10aril-C1-7alkil, C6-10ariloksi-C1-7alkil, heteroaril ili heterociklil u kojoj su alkil, aril, heteroaril i heterociklil opcijski supstituirani s 1 do 5 R7;
R2 je H, C1-7alkil, halo-C1-7alkil ili C3-7Cikloalkil;
R3 je H, halo, C1-7alkil, halo-C1-7alkil, C3-7cikloalkil, cijano, C1-7alkoksi, hidroksi, nitro, -NH2, -NH(C1-7alkil) ili -N(C1-7alkil)2;
svaki R4 je neovisno odabran iz skupine koja se sastoji od sljedećih: halo, C1-7alkil, halo-C1-7alkil, C3-7cikloalkil, cijano, -NH2, -NH(C1-7alkil), -N(C1-7alkil)2, C1-7alkoksi, halo-C1-7alkoksi, hidroksi, karboksi, nitro, sulfonil, sulfamoil, sulfonamido, C6-10aril, heterociklil, C6-10ariloksi, heterocikliloksi, -SH, -S-C1-7alkil, -C(O)O-aril, -C(O)O-heterociklil, -C(O)O-heteroaril, -C(O)NR2-C1-7alkil, -C(O)NR2-C6-10aril, -C(O)NR2-heteroaril, -C(O)NR2-heterociklil, -NR2C(O)-C1-7alkil, -NR2C(O)-C6-10aril, -NR2C(O)-heteroaril, -NR2C(O)-heterociklil, -OC(O)-C1-7alkil, -OC(O)-C6-10aril, -OC(O)-heteroaril i -OC(O)-heterociklil;
pri čemu R4 je opcijski supstituiran s 1 do 5 R7;
R5 i R6 su neovisno C1-7alkil, C3-7cikloalkil, halo-C1-7alkil, heterociklil;
Svaki R7je neovisno odabran iz skupine koja se sastoji od sljedećih: halo, C1-7alkil, C3-7cikloalkil, C1-7alkoksi, C6-10ariloksi, heterociklil, C6-10aril, heteroaril, CN i halo-C1-7alkil; i
p je 0, 1, 2, 3, 4 ili 5.
3. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da C je fenil.
4. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da je prsten C ili prsten C zajedno s dvije skupine R4, sljedeći:
[image]
[image]
gdje R8a je R8 ili H i R4a je R4 ili H.
5. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da je R4 neovisno odabran od sljedećih: C1-4alkil, C1-4alkoksi, CN, halo, halo-C1-4alkil ili halo-C1-7alkoksi.
6. Spoj prema bilo zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da R1 je C1-4alkil, R2 je H, R3 je H, A je CHR5, R6 je C1-4alkil ili C3-6cikloalkil, p je 1 ili 2; i
svaki R4 je neovisno C1-4alkil, halo-C1-4alkil, C1-4alkoksi, CN, halo ili halo-C1-4alkoksi.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je odabran od sljedećih:
N-(1-(5-(3-kloro-4-cijanofenil)piridin-3-il)-2-metilpropil)etansulfonamid;
N-(1-(5-(4-cijano-3-metoksifenil)piridin-3-il)etil)etansulfonamid;
N-(1-(5-(3-kloro-4-cijanofenil)piridin-3-il)etil)etansulfonamid;
N-(1-(5-(3-kloro-4-cijanofenil)piridin-3-il)butil)etansulfonamid;
(R)-N-((5-(3-kloro-4-cijanofenil)piridinil)(ciklopropil)metil)etansulfonamid;
(S)-N-((5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-((5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopropil)metil)metansulfonamid;
N-((5-(4-cijano-3-metoksifenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(S)-N-((5-(4-cijano-2-metoksifenil)piridin-3-l)(ciklopropil)metil)etansulfonamid;
(R)-N-((5-(4-cijano-2-metoksifenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(R)-N-((5-(4-cijano-3-fluorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(S)-N-((5-(4-cijano-3-fluorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-((5-(4-cijano-2-fluorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-((5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopentil)metil)etansulfonamid;
N-((5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopropil)metil)propan-2-sulfonamid;
N-(ciklopropil(5-(2-metoksifenil)piridin-3-il)metil)etansulfonamid;
N-((5-(2-klorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-((5-(4-cijanofenil)piridin-3-ciklopropil)metil)etansulfonamid;
N-(ciklopropil(5-(3-fluorofenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(4-metoksifenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(4-etoksifenil)piridin-3-il)metil)etansulfonamid;
N-((5-(3-klorofenil)piridin-3-il)(ciklopropil)metil)-etansulfonamid;
N-(ciklopropil(5-(4-fluorofenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(2,4-diklorofenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(3,5-dimetilfenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(3,5-diklorofenil)piridin-3-il)metil)etansulfonamid;
N-((5-(4-klorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-(ciklopropil(5-(4-(trifluorometoksi)fenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(2,3-diklorofenil)piridin-3-il)metil)etansulfonamid;
N-((5-(3-kloro-4-fluorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-(ciklopropil(5-(6-metoksinaftalen-2-il)piridin-3-il)metil)etansulfonamid;
N-((5-(6-kloro-1 -metil- 1H-benzo[d]imidazol-2-il)piridin-3il)metil)etansulfonamid;
N-((5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopropil)metil)-N-metiletansulfonamid;
N-(ciklopropil(5-(4-fluoro-3-metil-fenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(4-etilsulfanil-fenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(3-fluoro-4-metoksi-fenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(2,4-dimetoksi-fenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(4-metilsulfanil-fenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-benzo-[1,3]-dioksol-5-il-piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(2,3-dihidro-benzofuran-5-il)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(1H-indol-5-il)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(2,4,6-trimetil-fenil)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-benzo[b]tiofen-2-il-piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-(1 -metil- 1H-indol-5-il)piridin-3-il)metil)etansulfonamid;
N-(ciklopropil(5-naphtalen-1-il-piridin-3-il)metil)etansulfonamid;
({[5-(3-Kloro-4-cijano-fenil)-piridin-3-il]-ciklopropil-metil}-etansulfonil-amino)-octena kiselina-metilester;
etansulfonska kiselina-{[5-(3-kloro-4-cijano-fenil)-piridin-3-il]-ciklopropil-metil}-izobutil-amid;
etansulfonska kiselina-{[5-(3-kloro-4-cijano-fenil)-piridin-3-il]-ciklopropil-metil}-(2-hidroksi-etil)-amid;
N-((4-kloro-5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopropil)metil)-N-metilmetansulfonamid;
N-((5-(6-cijanonaftalen-2-il)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-(ciklopropil(5-(kinolin-6-il)piridin-3-il)metil)etansulfonamid;
(R)-N-((5-(4-cijano-3-metilfenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(S)-N-((5-(4-cijano-3-metilfenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-((5-(5-cijanobenzofuran-2-il)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-((5-(benzo[d]tiazol-5-il)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-((5-(benzofuran-5-il)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-(1-(5-(4-cijano-3-metilfenil)piridin-3-il)-2,2,2-trifluoroetil)etansulfonamid;
ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je odabran od sljedećih:
(R)-N-((5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(S)-N-((5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
N-((5-(3-kloro-4-cijanofenil)piridin-3-il)(ciklopropil)metil)metansulfonamid;
N-((5-(4-cijano-3-metoksifenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(S)-N-((5-(4-cijano-2-metoksifenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(R)-N-((5-(4-cijano-2-metoksifenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(R)-N-((5-(4-cijano-3-fluorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid;
(S)-N-((5-(4-cijano-3-fluorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid
N-((5-(4-cijano-2-fluorofenil)piridin-3-il)(ciklopropil)metil)etansulfonamid; ili
njegova farmaceutski prihvatljiva sol.
9. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 8, ili njegovu farmaceutski prihvatljivu sol, kao i jedan ili više farmaceutski prihvatljivih nosača.
10. Kombinacija, posebno farmaceutska kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 8, ili njegovu farmaceutski prihvatljivu sol, kao i jedan ili više terapeutski djelotvornih sredstava odabranih između inhibitora reduktaze HMG-Co-A, antagonista receptora angiotenzina II, inhibitora enzima koji pretvara angiotenzin (ACE), blokatora kanala kalcija (CCB), inhibitora enzima koji pretvara angiotenzin/inhibitora neutralne endopeptidaze (inhibitora ACE/NEP), antagonista endotelina, inhibitora renina, diuretika, ApoA-I-mimika, anti-dijabetskog sredstva, sredstva za smanjivanje pretilosti, blokatora receptora aldosterona, blokatora receptora endotelina, i CETP-inhibitora.
11. Spoj prema bilo kojem od zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava kao lijek.
12. Spoj prema bilo kojem od zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u liječenju osobe od poremećaja ili bolesti koji/a je posredovana sintezom aldosterona.
13. Spoj prema bilo kojem od zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, koji se upotrebljava u liječenju osobe od poremećaja ili bolesti, naznačen(a) time, da je poremećaj ili bolest posredovan/a abnormalnim djelovanjem sinteze aldosterona.
14. Spoj prema bilo kojem od zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u liječenju poremećaja ili bolesti odabranog/e između sljedećih:
hipokalemija, hipertenzija, Connova bolest, zastoj bubrega, kronični zastoj bubrega, restenoza, ateroskleroza, sindrom X, pretilost, nefropatija, post-miokardijski infarkt, koronarne srčane bolesti, povećanje tvorbe kolagena, fibroza i kardijalno remodeliranje koje slijedi zbog hipertenzije te endotelijalna disfunkcija, kardiovaskularne bolesti, renalna disfunkcija, bolesti jetre, cerebrovaskularne bolesti, vaskularne bolesti, retinopatija, neuropatija, inzulinopatija, edem, endotelijalna disfunkcija, baroreceptorna disfunkcija, migrenske glavobolje, srčani zastoj kao što je kongestivni srčani zastoj, aritmija, dijastolička disfunkcija, lijeva ventrikularna dijastolička disfunkcija, dijastolički srčani zastoj, oštećenje dijastoličkog punjenja, sistolička disfunkcija, ishemija, hipertrofična kardiomiopatija, nagla srčana smrt, miokardijska i vaskularna fibroza, oštećenje arterijskog integriteta, miokardijske nekrotičke lezije, vaskularno oštećenje, infarkt miokarda, lijeva ventrikularna hipertrofija, smanjenje ejekcijske frakcije, kardijske lezije, vaskularna hipertrofija stijenke, endotelijana zadebljanja, i fibrinoidna nekroza koronarnih arterija.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17867709P | 2009-05-15 | 2009-05-15 | |
US31841310P | 2010-03-29 | 2010-03-29 | |
PCT/EP2010/056572 WO2010130796A1 (en) | 2009-05-15 | 2010-05-12 | Aryl pyridine as aldosterone synthase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140371T1 true HRP20140371T1 (hr) | 2014-05-23 |
Family
ID=42288934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140371AT HRP20140371T1 (hr) | 2009-05-15 | 2014-04-22 | Arilpiridini kao inhibitori sinteze aldosterona |
Country Status (35)
Country | Link |
---|---|
US (3) | US8383827B2 (hr) |
EP (1) | EP2429995B1 (hr) |
JP (1) | JP5659224B2 (hr) |
KR (1) | KR101338555B1 (hr) |
CN (2) | CN102803217B (hr) |
AR (1) | AR076908A1 (hr) |
AU (1) | AU2010247414B2 (hr) |
BR (1) | BRPI1010600A2 (hr) |
CA (1) | CA2761859A1 (hr) |
CL (1) | CL2011002857A1 (hr) |
CO (1) | CO6470898A2 (hr) |
CR (1) | CR20110592A (hr) |
CU (1) | CU24045B1 (hr) |
DK (1) | DK2429995T3 (hr) |
EA (1) | EA020138B1 (hr) |
EC (1) | ECSP11011526A (hr) |
ES (1) | ES2459468T3 (hr) |
HK (1) | HK1163666A1 (hr) |
HR (1) | HRP20140371T1 (hr) |
IL (1) | IL216187A0 (hr) |
MA (1) | MA33358B1 (hr) |
MX (1) | MX2011012198A (hr) |
MY (1) | MY184008A (hr) |
NZ (1) | NZ596302A (hr) |
PE (1) | PE20120403A1 (hr) |
PL (1) | PL2429995T3 (hr) |
PT (1) | PT2429995E (hr) |
RS (1) | RS53275B (hr) |
SG (1) | SG175925A1 (hr) |
SI (1) | SI2429995T1 (hr) |
SV (1) | SV2011004061A (hr) |
TW (1) | TWI454460B (hr) |
UY (1) | UY32640A (hr) |
WO (1) | WO2010130796A1 (hr) |
ZA (1) | ZA201108155B (hr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
KR20120023091A (ko) | 2009-05-15 | 2012-03-12 | 노파르티스 아게 | 5-피리딘-3-일-1,3-디히드로-인돌-2-온 유도체, 및 알도스테론 신타제 및/또는 cyp11b1의 조절제로서의 그의 용도 |
WO2010130796A1 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
MX2011012199A (es) | 2009-05-15 | 2011-12-08 | Novartis Ag | Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. |
EP2480528B1 (en) | 2009-09-25 | 2018-08-29 | Oryzon Genomics, S.A. | Lysine specific demethylase-1 inhibitors and their use |
US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
JP5654608B2 (ja) | 2009-11-17 | 2015-01-14 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体 |
WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
MX2012012111A (es) | 2010-04-19 | 2013-05-30 | Oryzon Genomics Sa | Inhibidores de demetilasa-1 especifica de lisina y su uso. |
US9382226B2 (en) | 2010-07-21 | 2016-07-05 | Merck Sharp & Dohme Corp. | Aldosterone synthase inhibitors |
JP6054868B2 (ja) | 2010-07-29 | 2016-12-27 | オリゾン・ジェノミックス・ソシエダッド・アノニマOryzon Genomics S.A. | Lsd1のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用 |
WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
WO2012126275A1 (zh) * | 2011-03-18 | 2012-09-27 | 山东亨利医药科技有限责任公司 | 含有螺环的二氢吡唑类化合物 |
US20140296255A1 (en) * | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
EP2741741A2 (en) * | 2011-05-19 | 2014-06-18 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
BR112014006283B1 (pt) | 2011-09-15 | 2021-11-03 | F. Hoffmann-La Roche Ag | Novos derivados de dihidroquinolina-2-ona |
US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
US9351973B2 (en) | 2011-09-22 | 2016-05-31 | Merck Sharp & Dohme Corp. | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
EP2757883B1 (en) | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
CN104203914B (zh) | 2011-10-20 | 2017-07-11 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
CN102977085B (zh) * | 2011-10-27 | 2015-07-29 | 四川大学 | 2-芳基-苯并[d]噁唑、2-芳基-苯并[d]噻唑衍生物及其制备方法和用途 |
JP6302846B2 (ja) | 2012-02-22 | 2018-03-28 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Tnap阻害剤としてのスルホンアミド化合物およびその使用 |
US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
LT2956464T (lt) | 2013-02-14 | 2018-07-10 | Novartis Ag | Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai |
MX2016001020A (es) | 2013-07-25 | 2016-08-03 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca. |
US9340582B2 (en) | 2013-07-25 | 2016-05-17 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
MY176401A (en) * | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
AR100821A1 (es) * | 2014-06-18 | 2016-11-02 | Bayer Cropscience Ag | Pirazolil-triazolil-piridinas como agentes plaguicidas |
AR100817A1 (es) * | 2014-06-18 | 2016-11-02 | Bayer Cropscience Ag | Pirazoles y tetrazoles sustituidos con halógeno |
HUE043783T2 (hu) | 2014-10-15 | 2019-09-30 | Boehringer Ingelheim Int | Aldoszteron szintáz inhibitorok |
AU2016209968B2 (en) | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
JP6314196B2 (ja) * | 2015-10-22 | 2018-04-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2017069226A1 (ja) * | 2015-10-23 | 2017-04-27 | 田辺三菱製薬株式会社 | 新規含窒素芳香族複素環化合物 |
WO2018125799A2 (en) | 2016-12-29 | 2018-07-05 | Viamet Pharmaceuticals (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
RU2764666C2 (ru) | 2016-12-29 | 2022-01-19 | Селенити Терапьютикс (Бермуда), Лтд. | Соединения, ингибирующие металлоферменты |
EP3357910A1 (en) | 2017-02-02 | 2018-08-08 | Julius-Maximilians-Universität Würzburg | Compound for in vivo diagnosis of a dysfunction of adrenal glands |
WO2018165649A1 (en) | 2017-03-10 | 2018-09-13 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
MA51620A (fr) | 2018-01-19 | 2020-11-25 | Cytokinetics Inc | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
JP2022507958A (ja) | 2018-11-27 | 2022-01-18 | ノバルティス アーゲー | 代謝障害の治療用のプロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)阻害薬としての環状四量体化合物 |
CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽 |
JP2022530775A (ja) | 2019-05-01 | 2022-07-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | (r)-(2-メチルオキシラン-2-イル)メチル 4-ブロモベンゼンスルホネート |
JP2023546970A (ja) * | 2020-10-26 | 2023-11-08 | ミネラリス・セラピューティクス・インコーポレイテッド | 高血圧のためのcyp11b2ベータヒドロキシラーゼ阻害剤 |
CA3209557A1 (en) | 2021-03-04 | 2022-09-09 | Bradley P. Morgan | Cardiac sarcomere inhibitors |
WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
CN115304591A (zh) * | 2022-07-08 | 2022-11-08 | 广州中医药大学(广州中医药研究院) | 一种桥环甾体合成酶抑制剂及其制备方法和应用 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
EP0067511A3 (en) | 1981-05-19 | 1983-04-06 | Imperial Chemical Industries Plc | Method of inducing tillering using pyridine derivatives, and some of the pyridines themselves, process for preparing them and agricultural compositions containing them |
DE3347565A1 (de) | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
AU654331B2 (en) | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
AU660930B2 (en) | 1991-06-21 | 1995-07-13 | Novo Nordisk A/S | (S)(+)-2-ethoxy-4-(N-(1-(2-piperidinophenyl)-3-methyl-1- butyl)aminocarbonylmethyl)benzoic acid |
JP2508949B2 (ja) | 1991-07-30 | 1996-06-19 | 味の素株式会社 | N−(トランス−4−イソプロピルシクロヘキシルカルボニル)−d−フェニルアラニンの結晶及びその製造法 |
EP0618803A4 (en) | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
GB9504854D0 (en) | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
TW313568B (hr) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
IT1309067B1 (it) | 1999-01-22 | 2002-01-16 | Marino Scaburri | Sistema per il riscaldamento ad induzione di corpi in genere, inspecie per la cottura di cibi |
US6544974B2 (en) | 1999-09-23 | 2003-04-08 | G.D. Searle & Co. | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity |
DE60022386T2 (de) | 1999-12-16 | 2006-06-22 | Schering Corp. | Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten |
WO2002022579A2 (en) | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US7294624B2 (en) | 2001-12-20 | 2007-11-13 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
EP1532640A1 (en) | 2002-08-22 | 2005-05-25 | Agfa-Gevaert | Process for preparing a substantially transparent conductive layer |
US7618974B2 (en) | 2003-01-31 | 2009-11-17 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US7569591B2 (en) * | 2003-01-31 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US7582641B2 (en) | 2003-01-31 | 2009-09-01 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
ES2308477T3 (es) | 2004-03-26 | 2008-12-01 | Eli Lilly And Company | Compuestos para el tratamiento de la dislipidemia. |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
BRPI0513864A (pt) | 2004-07-28 | 2008-05-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades |
FR2876691B1 (fr) | 2004-10-18 | 2006-12-29 | Sanofi Aventis Sa | Derives de pyridine, leur preparation, leur application en therapeutique |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
JP2008519814A (ja) * | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
MX2007007330A (es) | 2004-12-16 | 2007-10-04 | Vertex Pharma | Piridonas de utilidad como inhibidores de quinasas . |
JP2006182697A (ja) | 2004-12-27 | 2006-07-13 | Kowa Co | スルホンアミド基を有する環状アミン化合物 |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
US7928127B2 (en) | 2005-05-19 | 2011-04-19 | Notre Dame University | Inhibitors of matrix metallaproteinases |
WO2007019344A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b] thiayole derivatives as sirtuin modulating compounds |
WO2007091140A1 (en) | 2006-02-06 | 2007-08-16 | Pfizer Products Inc. | Substituted phenylsulfamoyl compounds as ppar agonists |
DE102006012251A1 (de) | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
CN101484452A (zh) * | 2006-05-03 | 2009-07-15 | 阿斯利康(瑞典)有限公司 | 噻唑衍生物及其作为抗肿瘤药物的用途 |
EP2054056A4 (en) | 2006-08-16 | 2010-08-25 | J David Gladstone Inst A Testa | SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE |
PE20080769A1 (es) | 2006-09-08 | 2008-08-14 | Novartis Ag | Derivados de biaril-sulfonamida |
WO2008042867A2 (en) | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
CL2008001356A1 (es) | 2007-05-10 | 2008-11-14 | Smithkline Beecham Corp | Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares. |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
WO2008150827A1 (en) * | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
WO2009039140A1 (en) | 2007-09-17 | 2009-03-26 | Smithkline Beecham Corporation | Pyridopyrimidine derivatives as pi3 kinase inhibitors |
US8039493B2 (en) * | 2007-09-27 | 2011-10-18 | Hoffmann-La Roche Inc. | Biaryl sulfonamide derivatives |
US20100311736A1 (en) * | 2007-10-22 | 2010-12-09 | Glaxosmithkline Llc | Pyridosulfonamide derivatives as p13 kinase inhibitors |
UA102828C2 (en) | 2007-11-27 | 2013-08-27 | Целльзом Лимитед | Amino triazoles as p13k inhibitors |
AU2008343813B2 (en) | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
WO2009096198A1 (ja) | 2008-02-01 | 2009-08-06 | Pharma Ip Limited Liability Intermediary Corporations | 新規ビアリール誘導体 |
WO2009147187A1 (en) * | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
AR072297A1 (es) * | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
US8729074B2 (en) | 2009-03-20 | 2014-05-20 | Amgen Inc. | Inhibitors of PI3 kinase |
MX2011012199A (es) * | 2009-05-15 | 2011-12-08 | Novartis Ag | Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. |
WO2010130796A1 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
-
2010
- 2010-05-12 WO PCT/EP2010/056572 patent/WO2010130796A1/en active Application Filing
- 2010-05-12 CN CN201080031608.0A patent/CN102803217B/zh not_active Expired - Fee Related
- 2010-05-12 NZ NZ596302A patent/NZ596302A/en not_active IP Right Cessation
- 2010-05-12 RS RS20140197A patent/RS53275B/en unknown
- 2010-05-12 CN CN201510199731.8A patent/CN104892502B/zh not_active Expired - Fee Related
- 2010-05-12 BR BRPI1010600A patent/BRPI1010600A2/pt not_active IP Right Cessation
- 2010-05-12 DK DK10719758.4T patent/DK2429995T3/da active
- 2010-05-12 EA EA201101618A patent/EA020138B1/ru not_active IP Right Cessation
- 2010-05-12 PL PL10719758T patent/PL2429995T3/pl unknown
- 2010-05-12 MA MA34443A patent/MA33358B1/fr unknown
- 2010-05-12 EP EP10719758.4A patent/EP2429995B1/en active Active
- 2010-05-12 JP JP2012510298A patent/JP5659224B2/ja not_active Expired - Fee Related
- 2010-05-12 SI SI201030590T patent/SI2429995T1/sl unknown
- 2010-05-12 MY MYPI2011005369A patent/MY184008A/en unknown
- 2010-05-12 PE PE2011001960A patent/PE20120403A1/es not_active Application Discontinuation
- 2010-05-12 MX MX2011012198A patent/MX2011012198A/es active IP Right Grant
- 2010-05-12 KR KR1020117029918A patent/KR101338555B1/ko not_active IP Right Cessation
- 2010-05-12 ES ES10719758.4T patent/ES2459468T3/es active Active
- 2010-05-12 CA CA2761859A patent/CA2761859A1/en not_active Abandoned
- 2010-05-12 AU AU2010247414A patent/AU2010247414B2/en not_active Ceased
- 2010-05-12 PT PT107197584T patent/PT2429995E/pt unknown
- 2010-05-12 SG SG2011081908A patent/SG175925A1/en unknown
- 2010-05-13 AR ARP100101666A patent/AR076908A1/es unknown
- 2010-05-14 US US12/780,025 patent/US8383827B2/en not_active Expired - Fee Related
- 2010-05-14 UY UY0001032640A patent/UY32640A/es not_active Application Discontinuation
- 2010-05-14 TW TW099115568A patent/TWI454460B/zh not_active IP Right Cessation
-
2011
- 2011-11-07 ZA ZA2011/08155A patent/ZA201108155B/en unknown
- 2011-11-07 IL IL216187A patent/IL216187A0/en unknown
- 2011-11-11 CR CR20110592A patent/CR20110592A/es unknown
- 2011-11-14 SV SV2011004061A patent/SV2011004061A/es unknown
- 2011-11-14 CU CU2011000207A patent/CU24045B1/es not_active IP Right Cessation
- 2011-11-14 CL CL2011002857A patent/CL2011002857A1/es unknown
- 2011-12-14 EC EC2011011526A patent/ECSP11011526A/es unknown
- 2011-12-15 CO CO11173249A patent/CO6470898A2/es active IP Right Grant
-
2012
- 2012-04-20 HK HK12103975.9A patent/HK1163666A1/xx not_active IP Right Cessation
- 2012-09-14 US US13/615,902 patent/US8519142B2/en not_active Expired - Fee Related
-
2013
- 2013-07-11 US US13/939,232 patent/US8809545B2/en not_active Expired - Fee Related
-
2014
- 2014-04-22 HR HRP20140371AT patent/HRP20140371T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140371T1 (hr) | Arilpiridini kao inhibitori sinteze aldosterona | |
EA200900811A1 (ru) | Имидазолы в качестве ингибиторов альдостеронсинтазы | |
PE20080944A1 (es) | Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5) | |
ES2552733T3 (es) | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos | |
RU2011147181A (ru) | Азетидинилдиамиды в качестве ингибиторов моноациглицерин-липазы | |
RU2006132463A (ru) | Антагонисты рецептора хемокина | |
UY25904A1 (es) | Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina | |
HRP20161378T1 (hr) | Dihidropiridon kao faktor xia inhibitora | |
AU2010302572B2 (en) | New histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers | |
AR056008A1 (es) | Derivados de pirazina antagonistas del receptor a2b de adenosina | |
RU2008150752A (ru) | Ингибиторы альдостеронсинтазы и/или 11-гидроксилазы | |
RU2014113926A (ru) | АМИДОСОЕДИНЕНИЯ В КАЧЕСТВЕ RORγT МОДУЛЯТОРОВ И ИХ ПРИМЕНЕНИЕ | |
AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
CA2437122A1 (en) | Quinazolines as mmp-13 inhibitors | |
AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
CN101115482A (zh) | 杂环天冬氨酰蛋白酶抑制剂 | |
HRP20140691T1 (hr) | Supstituirani derivati karbamoilmetilamino octene kiseline kao novi nep-inhibitori | |
MA29119B1 (fr) | Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases | |
HRP20130047T1 (hr) | Supstituirani pirolidin-2-karboksamidi | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
AR040017A1 (es) | Combinacion de compuestos organicos | |
RU2012104244A (ru) | Аналоги tofa, применимые при лечении дерматологических расстройств или состояний | |
RU2007132670A (ru) | Индолин-сульфонамидные соединения | |
AR114156A1 (es) | MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTE | |
NZ588374A (en) | Tetrazole compounds for reducing uric acid |